The global clinical oncology next-generation sequencing (NGS) market is on a trajectory of exceptional growth, with projections indicating a leap from USD 635 million in 2024 to USD 3,131.5 million by 2034. This remarkable expansion, driven by a 17.3% compound annual growth rate (CAGR), underscores the transformative impact of NGS technology in redefining cancer diagnosis …